Safety and pharmacokinetics of recombinant human superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome

Pediatrics

Volumn 97, Issue 6 I, 1996, Pages 811-817

  Rosenfeld, Warren N ^a   Davis, Jonathan M ^a   Parton, Lance ^a   Richter, Susan E ^a   Price, Anita ^a   Flaster, Edith ^a   Kassem, Nadim ^b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b Bio Technology General Corporation   (United States)

Author keywords

antioxidants; pharmacokinetics; respiratory distress syndrome; superoxide dismutase

Indexed keywords

SUPEROXIDE DISMUTASE;

ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ENZYME ACTIVITY; HUMAN; INFANT; INFLAMMATION; INTRATHECAL DRUG ADMINISTRATION; NEUTROPHIL CHEMOTAXIS; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; TREATMENT OUTCOME;

DRUG MONITORING; FEMALE; HUMANS; INFANT, NEWBORN; INFLAMMATION; INSTILLATION, DRUG; MALE; RECOMBINANT PROTEINS; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SUPEROXIDE DISMUTASE; TRACHEA;

EID: 0030047376     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bancalari E, Abdenour GE, Feller R, et al. Bronchopulmonary dysplasia: clinical presentation. J Pediatr. 1979;95:819-823
2. Tooley WH. Epidemiology of bronchopulmonary dysplasia. Pediatrics. 1979;95:851-855
3. Soll RF, McQueen MC. Respiratory distress syndrome. In: Sinclair JC Bracken MB, eds. Effective Care of the Newborn Infant. New York: Oxford University Press; 1992:325-358
4. Bregman J, Farrell EE. Neurodevelopmental outcome in infants with bronchopulmonary dysplasia. Clin Perinatal. 1990;19:673-694
5. Davis JM, Rosenfeld W. Chronic lung disease. In: Avery GB, Fletcher MA, MacDonald MD, eds. Neonatology, Philadelphia: J.B. Lipincott Co.; 1994:453-477
6. Bagchi A, Viscardi RM, Taciak V, Ensor JE, McCrea KA, Hasday JD. Increased activity of interleukin-6 but not tumor necrosis factor α in lung lavage of premature infants is associated with the development of bronchopulmonary dysplasia. Pediatr Res. 1994;36:244-252
7. Merritt TA, Cochrane CG, Holcomb K, et al. Elastase and α-1 proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome: role of inflammation in the pathogenesis of bronchopulmonary dysplasia. J Clin Invest. 1983;72:656-666
8. 2 rich environment: the antioxidant enzymes in the developing rabbit lung. Pediatr Res. 1984;18:240-244
9. Frank L. Developmental aspects of experimental pulmonary oxygen toxicity. Free Radical Biol Med. 1991;11:463-494
10. Davis JM, Rosenfeld WN, Sanders RJ, Gonenne A. Prophylactic effects of recombinant human superoxide dismutase in neonatal lung injury. J Appl Physiol 1993;74:2234-2241
11. Turrens JF, Crapo JD, Freeman BA. Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase. J Clin Invest. 1984;73:87-95
12. Padmanabhan RV, Gudapaty R, Liener JE, Schwartz BA, Hoidal JR. Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase. Am Rev Respir Dis. 1985;132:164-167
13. Rosenfeld W, Evans H, Concepcion L, Jhaveri R, Schaeffer H, Friedman A. Prevention of bronchopulmonary dysplasia by administration of bovine superoxide dismutase in preterm infants with respiratory distress syndrome. J Pediatr. 1984;105:781-785
14. Matalon S, Holm BA, Baker RR, Whitefield MK, Freeman BA. Characterization of antioxidant activities of pulmonary surfactant mixtures. Biochem Biophys Acta. 1990;1035:121-127
15. McCord JM, Fridovich I. Superoxide dismutase: an enzymatic function for erythrocuprein. J Biol Chem. 1969;244:6049-6055
16. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest. 1968;21(Suppl)97:77-89
17. Gallin JI, Clark RA, Goetzl EJ. Radioassay of leukocyte locomotion: a scientific technique for clinical studies. In: Gallin JI, Quie PG, eds. Leukocyte Chemotaxis. New York, NY: Raven Press; 1978:79-86
18. Richardson DK, Gray JE, McCormick MC, Workman K, Goldmann DA. Score for neonatal acute physiology: a physiologic severity for neonatal intensive care. Pediatrics. 1993;91:617-623
19. Toce SS, Farrell PM, Leavitt LA, Samuels DP, Edwards DK. Clinical and radiographic scoring systems for assessing bronchopulmonary dysplasia. Am J Dis Child. 1984;138:581-585
20. Merritt TA. Oxygen exposure in the newborn guinea pig lung lavage cell populations, chemotactic and elastase response: a possible relationship to neonatal bronchopulmonary dysplasia. Pediatr Res. 1982;16:798-805
21. De Los Santos R, Seidenfeld JJ, Anzueto JF, et al. One hundred percent oxygen lung injury in adult baboons. Am Rev Respir Dis. 1987;136: 657-661
22. Ehrenkranz RA, Ablow RC, Warshaw JB. Effect of vitamin E on the development of oxygen-induced lung injury in neonates. Ann NY Acad Sci. 1982;393:452-466
23. Saldanha RL, Cepeda EE, Poland RL. The effect of vitamin E prophylaxis on the incidence and severity of bronchopulmonary dysplasia. J Pediatr. 1982;101:89-93
24. Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med. 1989;320:1505-1510
25. Collaborative Dexamethasone Trial Group. Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Pediatr. 1991;88:421-427
26. Harkavy KL, Scanlon JW, Chowdhry PK, Grylack LJ. Dexamethasone therapy for chronic lung disease in ventilator-and oxygen-dependent infants: a controlled trial. J Pediatr. 1989;115:979-983
27. Davis JM, Sinkin RA, Aranda JV. Drug therapy for bronchopulmonary dysplasia. Pediatr Pulmonol. 1990;8:117-125
28. BioTechnology General Corporation. Investigators Brochure: FDA Report of Clinical Trial for Evaluation of Intravenous rhSOD in Premature Neonates With Respiratory Distress Syndrome. Iselin, NJ: BioTechnology General Corporation; 1994. Study 102
29. Sahgal N, Davis JM, Robbins CG, Horowitz S, Langenback EG, Perry RH, Colflesh D, Tierney J, Simon SR. Localization and activity of recombinant human CuZn superoxide dismutase following intratracheal administration. Am J Physiol. In press
30. Sahgal N, Kleinman LI, Lorenz JM, Markarian K. Plasma creatinine is a poor predictor of changes in glomerular filtration rate in extremely low birth weight (ELBW) neonates. Clin Res. 1993;41:619A
31. Thibeault DW, Rezaiekhaligh E, Mabry S, Beringer T. Prevention of chronic pulmonary oxygen toxicity in young rats with liposome encapsulated catalase administered intratracheally. Pediatr Pulmonol. 1991;11: 318-327
32. Ment LR, Stewart WB, Duncan CC. Beagle puppy model of intraventricular hemorrhage: effect of superoxide dismutase on cerebral blood flow and prostaglandins. J Neurosurg. 1985;62:563-569